Compare NOMD & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOMD | HRMY |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2015 | 2020 |
| Metric | NOMD | HRMY |
|---|---|---|
| Price | $10.35 | $28.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $14.25 | ★ $46.70 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 6.69% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 2.71 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | N/A | $19.87 |
| Revenue Next Year | $0.36 | $12.49 |
| P/E Ratio | ★ $8.38 | $10.57 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $9.82 | $25.52 |
| 52 Week High | $20.22 | $40.87 |
| Indicator | NOMD | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 26.20 | 34.40 |
| Support Level | N/A | $27.66 |
| Resistance Level | $12.36 | $37.38 |
| Average True Range (ATR) | 0.35 | 1.59 |
| MACD | -0.18 | 0.08 |
| Stochastic Oscillator | 15.80 | 35.66 |
Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distribution of branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Scandinavia, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.